%0 Journal Article
%A Gaughan, Elizabeth M
%A Kim, Miso
%A Mendez, Ignacio
%A Rao, Aparna D
%A Wei, Maria
%A So, Alexandra
%A Zhong, Xiaochen
%A Berking, Carola
%A Jiang, Ruixuan
%A Kim, Tae Min
%A Dalle, Stéphane
%A Robert, Caroline
%A Danson, Sarah
%A Alam, Salma
%A Charles, Julie
%A Davies, Tessa
%A Debus, Dirk
%A Dzienis, Marcin
%A Frazer, Ricky
%A Gebhardt, Christoffer
%A Geidel, Glenn
%A Hassel, Jessica
%A Hansen, Inga
%A Heppt, Markus Vincent
%A Hildebrandt, Lina
%A Isaacs, James M
%A Suh, Koung Jin
%A Keam, Bhumsuk
%A Kim, Yu Jung
%A Lesimple, Thierry
%A Saiag, Philippe
%A Delibes, Alicia
%A Barnett, Rosemarie
%A Krepler, Clemens
%A Gandhi, Kavita
%A Qizilbash, Nawab
%A Shui, Irene M
%A Tan, Xiang-Lin
%A Sullivan, Ryan J
%T Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.
%J Journal for ImmunoTherapy of Cancer
%V 14
%N 3
%@ 2051-1426
%C London
%I BioMed Central
%M DKFZ-2026-00557
%P e014564
%D 2026
%Z #NCTZFB9#
%X Anti-programmed cell death protein 1 (PD-1) immunotherapy has revolutionized the treatment of stage III and IV melanoma. Real-world data on its resistance is needed to facilitate the development of combinatorial approaches to overcome anti-PD-1 resistance.To characterize anti-PD-1 resistance and assess whether progressive disease assigned by clinicians is concordant with scan data assessed by independent central reviewers (ICR).A retrospective chart review was conducted in adult patients with stage III/IV melanoma who initiated anti-PD-1 therapy from January 2018 until 12 months before the start of data collection at 22 sites across six countries. Primary resistance and late relapse in the adjuvant setting, and primary, secondary resistance, and late progression in the advanced setting were assigned using Society for Immunotherapy of Cancer definitions. Demographic and clinical characteristics by type of resistance were compared with appropriate univariate tests. Time to resistance (TTR) and overall survival were analyzed using Kaplan-Meier. To compare the concordance of progression assigned by clinicians and ICR, the positive predictive value (PPV) was calculated in a subset of patients.Of 981 eligible patients, 738 were included. In the adjuvant setting (n=240), 53 (22.1
%K Humans
%K Melanoma: drug therapy
%K Melanoma: pathology
%K Melanoma: mortality
%K Melanoma: immunology
%K Male
%K Female
%K Retrospective Studies
%K Middle Aged
%K Neoplasm Staging
%K Drug Resistance, Neoplasm
%K Aged
%K Immune Checkpoint Inhibitors: therapeutic use
%K Immune Checkpoint Inhibitors: pharmacology
%K Adult
%K Immunotherapy: methods
%K Programmed Cell Death 1 Receptor: antagonists & inhibitors
%K Skin Neoplasms: drug therapy
%K Skin Neoplasms: pathology
%K Aged, 80 and over
%K Adjuvant (Other)
%K Immune Checkpoint Inhibitor (Other)
%K Immunotherapy (Other)
%K Melanoma (Other)
%K Immune Checkpoint Inhibitors (NLM Chemicals)
%K Programmed Cell Death 1 Receptor (NLM Chemicals)
%K PDCD1 protein, human (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41786455
%2 pmc:PMC12970133
%R 10.1136/jitc-2025-014564
%U https://inrepo02.dkfz.de/record/310361